Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Rising Leverage ⢠Weaker Profitability TMDX has strong liquidity and a more reasonable valuation, but deteriorating margins, cash flow, rising leverage, dilution, and negative retained earnings warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Oversold momentum ⢠Support test Support Level: $82.00â$84.00 Resistance Level: $88.00â$90.00 TMDX is in a last-month downtrend below its 21-day average, but oversold RSI near support at $82â84 may favor a short-term bounce unless $82 breaks; watch $88â90 resistance for trend improvement.
Sentiment & News
Key News Insights: ⢠Expansion Strategy ⢠Margin Pressure ⢠Governance Probes TransMedics' growth strategy, new CFO, and institutional interest support momentum, but investment-driven margin pressure and governance probes remain key risks.
AI Summary
TMDX's investment case now hinges on proving that kidney, European logistics, and broader organ-platform adoption can convert 22%â25% revenue growth into renewed EBITDA-margin expansion and materially higher free cash flow, rather than further debt-funded expense growth; monitor upcoming margin, utilization, and cash-flow trends before treating the oversold share price as a durable opportunity.
Description
TransMedics Group is a commercial-stage medical technology company that develops and commercializes portable systems for perfusion, preservation and monitoring of donor organs to support transplantation in the U.S. and abroad. Its Organ Care System recreates near-physiologic conditions ex vivo and includes device variants for lungs, hearts and livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 25 | Jan 1 | TMDX | TransMedics Group, Inc. | TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea. | Closed | -4.2% |
| Sep 8 | Sep 15 | TMDX | TransMedics Group, Inc. | TransMedics delivered robust Q2 revenue (+38% YoY), raised 2025 guidance, received an FDA conditional approval for a key trial (Aug 2025), and shows strong technical momentum with clear near-term catalysts, although ongoing litigation and valuation levels advise cautious position sizing. | Closed | +8.3% |